Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00403988
Status:
TERMINATED
Last Update Posted:
2008-11-04
First Post:
2006-11-23
Brief Title:
Vinorelbine and Oxaliplatin Vinox With or Without Trastuzumab Herceptin in Advanced Breast Carcinoma
Sponsor:
American University of Beirut Medical Center
Organization:
American University of Beirut Medical Center
Study Overview
Official Title:
A Clinical Phase II Study of Vinorelbine and Oxaliplatin Vinox With or Without Trastuzumab Herceptin in Advanced Breast Carcinoma
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The results of a same study design have shown low response with important side effects Accordingly ethicly the study has been stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study Objective
To assess the efficacy and the safety of the combination of Oxaliplatin and Vinorelbine with or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer
To assess the efficacy and the safety of the combination of Oxaliplatin and Vinorelbine with or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None